Fewer brolucizumab injections needed to achieve sustained dryness in wet AMD
Click Here to Manage Email Alerts
Through 96 weeks, patients with neovascular age-related macular degeneration required fewer brolucizumab injections compared with aflibercept injections to achieve sustained retinal dryness.
“Brolucizumab had faster and statistically significantly higher rates of complete sustained drying in both studies over the entire trial time frame. This was achieved with fewer doses compared to aflibercept, suggesting better disease control with brolucizumab in neovascular age-related macular degeneration, with the potential for reduced treatment burden,” Carl D. Regillo, MD, said at the virtual American Society of Retina Specialists meeting.
Regillo and colleagues completed a post hoc analysis of the HAWK and HARRIER phase 3 prospective trials to evaluate the number of injections required to achieve sustained retinal dryness over 96 weeks for patients receiving brolucizumab or aflibercept. Sustained dryness was defined as three or more consecutive intraretinal fluid- and subretinal fluid-free visits, Regillo said.
The HAWK trial showed more than 50% of participants treated with both 3 mg and 6 mg brolucizumab achieved sustained dryness by week 8 compared with patients treated with aflibercept patients who achieved dryness by week 12. All patients achieved sustained dryness with the same number of weighted injections. more than 75% of patients treated with 6 mg brolucizumab achieved sustained dryness by week 32 with a mean 3.3 injections compared with week 36 and 3.7 mean injections for 3 mg brolucizumab. Both achieved dryness quicker and with fewer injections than patients who received aflibercept 2 mg, who achieved sustained dryness by week 56 with a mean 5.4 injections, he said.
The HARRIER trial showed similar results. More than 50% of patients in the brolucizumab 6 mg cohort experienced sustained dryness by week 4 with two mean injections compared with week 8 and 2.3 injections for patients treated with aflibercept 2 mg. More than 75% of patients treated with brolucizumab achieved sustained dryness by week 20 with a mean 2.6 injections compared with week 52 and 4.4 mean injections for patients treated with aflibercept, he said.
“The studies do show that there is definitely more favorable, more significantly faster, at both the 50th and 75th percentile, sustained drying with brolucizumab vs. aflibercept in patients over the course of the HAWK and HARRIER phase 3 studies, and with fewer injections,” Regillo said during discussion of the study.
Collapse
Regillo CD, et al. Number of injections and time to dry analysis of brolucizumab versus aflibercept in patients with neovascular AMD: 96-week data from HAWK and HARRIER. Presented at: American Society of Retina Specialists annual meeting; July 24-26, 2020 (virtual meeting).
Read more about
Click Here to Manage Email Alerts